Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Martin

Showing results (211-220 of 278) with videos related to

Pageof 28
Sort By:
Breast Cancer Research and Treatment|February 25, 2016
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-studyMiguel Martin, Jan C Brase, Amparo Ruiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast CancerJoanne L Blum, A Douglas Laird, Jennifer K Litton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancerJohn R Mackey, Manuel Ramos-Vazquez, Oleg Lipatov, et al.
Breast Cancer Research and Treatment|April 17, 2016
Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trialMilagros González-Rivera, Miriam Lobo, Sara López-Tarruella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2019
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>-</sup> Breast CancerSara A Hurvitz, Miguel Martin, Michael F Press, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensVicente Valero, John Forbes, Mark D Pegram, et al.
The Lancet. Oncology|December 14, 2012
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trialPaul E Goss, Ian E Smith, Joyce O'Shaughnessy, et al.
Cell|November 16, 2019
B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast CancerDaniel P Hollern, Nuo Xu, Aatish Thennavan, et al.
The Oncologist|July 2, 2013
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 StudyHeather-Jane Au, Wolfgang Eiermann, Nicholas J Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyMichael F Press, Guido Sauter, Marc Buyse, et al.
Pageof 28

Showing results (211-220 of 278) with videos related to

Sort By:
Pageof 28
Breast Cancer Research and Treatment|February 25, 2016
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-studyMiguel Martin, Jan C Brase, Amparo Ruiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast CancerJoanne L Blum, A Douglas Laird, Jennifer K Litton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancerJohn R Mackey, Manuel Ramos-Vazquez, Oleg Lipatov, et al.
Breast Cancer Research and Treatment|April 17, 2016
Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trialMilagros González-Rivera, Miriam Lobo, Sara López-Tarruella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2019
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>-</sup> Breast CancerSara A Hurvitz, Miguel Martin, Michael F Press, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensVicente Valero, John Forbes, Mark D Pegram, et al.
The Lancet. Oncology|December 14, 2012
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trialPaul E Goss, Ian E Smith, Joyce O'Shaughnessy, et al.
Cell|November 16, 2019
B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast CancerDaniel P Hollern, Nuo Xu, Aatish Thennavan, et al.
The Oncologist|July 2, 2013
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 StudyHeather-Jane Au, Wolfgang Eiermann, Nicholas J Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyMichael F Press, Guido Sauter, Marc Buyse, et al.
Pageof 28